Abel et al. reported in 7399 HR+ /HER2- breast cancer patients (5902 IDC and 1497 ILC) with available MammaPrint assay results, patients with ILC had a significant chance of falling into a discordant risk category, compared to those with IDC (46.8% versus 37.1%, p < 0.001). Here, ERBB2 is linked to breast cancer.